Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2022-07-28 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Record Date
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from the Board of Directors dated July 28, 2022, regarding the approval of unaudited financial results for the first quarter ended June 30, 2022. It includes a Limited Review Report by the statutory auditors Deloitte Haskins & Sells LLP, which reviews the interim consolidated financial results. The document contains extensive financial data, including income, expenses, profit before tax, tax expenses, and earnings per share, as well as notes explaining the results and related corporate actions such as dividend declarations and share capital changes. The presence of comprehensive financial statements and analysis for a quarter indicates this is an Interim / Quarterly Report. The document is not merely an announcement or a certification but contains substantive financial data and management discussion. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2022-07-28 English
Dividend
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from the Board of Directors of Dr. Lal PathLabs Limited dated July 28, 2022, reporting the approval of unaudited financial results for the first quarter ended June 30, 2022. It includes a Limited Review Report by the statutory auditors Deloitte Haskins & Sells LLP, which is typical for interim financial results. The document also declares an interim dividend and provides detailed consolidated financial data for the quarter, including income, expenses, profit before tax, tax expenses, and earnings per share. The presence of detailed financial statements and auditor's review confirms this is a comprehensive interim financial report rather than a brief announcement or certification. The document references compliance with SEBI Listing Regulations and Indian Accounting Standard 34 for interim financial reporting, further confirming its nature as an interim/quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2022-07-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 98% confidence The document is a detailed announcement of the outcome of a Board Meeting held on July 28, 2022, where the Board approved the unaudited financial results for the first quarter ended June 30, 2022. It includes the financial results themselves, detailed financial tables, notes explaining the results, and an independent auditor's review report by Deloitte Haskins & Sells LLP. The presence of actual financial data, comprehensive financial statements, and auditor's review indicates this is a substantive interim financial report. The document also mentions the declaration of an interim dividend, but the primary content is the financial results and auditor's review for the quarter. This fits the definition of an Interim / Quarterly Report (IR), which must contain actual financial statements or substantive financial data and analysis for a period shorter than a full fiscal year. The document is about 15,000 characters long, well beyond a brief announcement or certification, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is IR with high confidence. Q1 2023
2022-07-28 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings
2022-07-25 English
Board Meeting — Dividend/Financial results
Regulatory Filings Classification · 100% confidence The document text contains no substantive content, only placeholders for images and no textual information. The true document length is only 107 characters, which is extremely short and does not contain any report or announcement details. Given the lack of content, this cannot be classified as a report or detailed filing. It is most consistent with a Regulatory Filing (RNS) as a fallback category for documents that do not fit elsewhere.
2022-07-20 English
General updates
Regulatory Filings
2022-07-15 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.